The results of Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA), a phase III, randomised, double-blind, multinational study comparing the efficacy and safety of radium-223 versus placebo in patients with castration-resistant prostate cancer and bone metastases have been reported by Dr Chris Parker and colleagues in The New England Journal of Medicine. The authors concluded that in this study, which was terminated for efficacy at the pre-specified interim analysis, radium-223 improved overall survival. Read more here.
Study mentioned: Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. PMID: 23863050
No comments:
Post a Comment